vaginal bromocriptine and dienogest on the treatment of adenomyosis
Phase 2
- Conditions
- Adenomyosis.
- Registration Number
- IRCT20230407057838N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
History of 6 months of painful and regular menstruation
Exclusion Criteria
having a history of specific diseases (including epilepsy, gastrointestinal, cardiovascular, renal disorders) according to the person's own statement.
allergies to dienogest and bromocriptine
Presence of significant gynecological disease or abdominal and pelvic surgery in the last 6 months
- Not using gonadotropin agonist or antagonist, hormonal contraceptive in the last three months.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain. Timepoint: The intensity of pain at the beginning of the study (before the start of the intervention) and 3, 6 and 9 months after the start of taking the drugs vaginal bromocriptine and dinogest. Method of measurement: Visual pain measurement tool questionnaires are used to evaluate pain.;Blood loss. Timepoint: The amount of bleeding is checked at the beginning of the study (before the start of the intervention) and 3, 6, and 9 months after starting the use of vaginal bromocriptine and dinogest. Method of measurement: A visual chart of blood loss is used to evaluate changes in menstrual symptoms.
- Secondary Outcome Measures
Name Time Method State of uterine view. Timepoint: The condition of the uterus is checked at the beginning of the study (before the start of the intervention) and 6, and 9 months after starting the use of vaginal bromocriptine and dinogest. Method of measurement: Vaginal ultrasound.